All In Biotech

Free tool

FAERS Monitor: Inpefa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 216203 or its brand name (Inpefa, Sotagliflozin). Reports on generic versions are filed under their own applications.

Reports

557

Serious

202

36% of reports

Hospitalization

108

Death reported

50

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dizziness54
  • diarrhoea50
  • death47
  • therapy interrupted37
  • dyspnoea28
  • off label use27
  • product use issue27
  • urinary tract infection25
  • headache23
  • nausea19
  • fungal infection17
  • drug ineffective15
  • fatigue15
  • vomiting15
  • malaise14

Reports by year received

View as table
YearReports
20186
20193
20203
20212
20221
202345
2024296
2025146
202655

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,602 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
therapy interruptedSignal3719.614.3635
fungal infectionSignal1719.312.1277
urinary tract infectionSignal255.53.889
product use issueSignal275.43.894
dizzinessSignal544.13.2126
diarrhoeaSignal502.92.263
deathSignal472.11.626
dyspnoea281.91.311
headache231.40.92
malaise141.20.70
vomiting151.20.70
off label use271.20.80
nausea190.90.60
fatigue150.70.41
drug ineffective150.40.312

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.